Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04430036
Title AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors The University of Texas Health Science Center at San Antonio

bladder urothelial carcinoma


Balstilimab + Cisplatin + Gemcitabine + Zalifrelimab

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.